A fixed-dose subcutaneous combination of PER and TRA (Phesgo®; Genentech Co., Ltd., San Francisco, CA, USA) has also become available in Japan to treat HER2-positive breast cancer since September 2023. Here, ERBB2 is linked to breast cancer.